Top Page
Allergy Therapeutics
(LSE:AGY)
Allergy Therapeutics (AGY) vs. iShares MSCI United Kingdom ETF (EWC)
Allergy Therapeutics Business Overview & Revenue Model
Allergy Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 55.04M | 55.04M | 55.20M | 59.59M | 72.77M | 84.33M |
| Gross Profit | 25.13M | 25.13M | 29.74M | 32.69M | 48.95M | 61.80M |
| EBITDA | -29.43M | -29.43M | -30.74M | -36.24M | -8.69M | 7.61M |
| Net Income | -40.13M | -40.13M | -40.22M | -43.07M | -13.78M | 2.89M |
Balance Sheet | ||||||
| Total Assets | 67.54M | 67.54M | 64.83M | 66.77M | 72.95M | 88.09M |
| Cash, Cash Equivalents and Short-Term Investments | 12.79M | 12.79M | 12.91M | 14.85M | 20.52M | 40.27M |
| Total Debt | 60.09M | 60.09M | 30.99M | 35.99M | 10.53M | 11.17M |
| Total Liabilities | 95.74M | 95.74M | 61.12M | 64.70M | 35.18M | 39.55M |
| Stockholders Equity | -28.19M | -28.19M | 3.71M | 2.07M | 37.77M | 48.53M |
Cash Flow | ||||||
| Free Cash Flow | -31.98M | -31.98M | -35.54M | -35.59M | -17.17M | 5.95M |
| Operating Cash Flow | -28.72M | -28.72M | -32.14M | -30.92M | -14.11M | 8.52M |
| Investing Cash Flow | -3.15M | -3.15M | -1.20M | -4.67M | -3.06M | -2.76M |
| Financing Cash Flow | 32.04M | 32.04M | 31.43M | 29.91M | -2.64M | -2.03M |
Allergy Therapeutics Technical Analysis
Allergy Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £3.37B | 11.80 | 15.66% | 4.16% | 3.73% | 27.13% | |
67 Neutral | £195.40M | -7.98 | 2.83% | 2.18% | 8.74% | -166.50% | |
65 Neutral | £82.75M | ― | ― | ― | ― | ― | |
63 Neutral | £114.81M | -5.78 | -396.71% | ― | 93.48% | 51.18% | |
57 Neutral | £730.83M | -14.17 | ― | ― | -0.28% | 22.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Allergy Therapeutics Corporate Events
Allergy Therapeutics has published the notice of its 2025 Annual General Meeting, following release of its annual report and accounts for the year ended 30 June 2025, with meeting documents now available to shareholders via the company’s website. The company is asking shareholders to approve the appointment of two new board members, former HSBC vice chairman Helge Weiner-Trapness as executive director and chief strategy officer, and Adicon CFO Lawrence Allen Wang as a non-executive director, both bringing substantial investment banking and healthcare experience in Asia. Management believes these additions will support Allergy Therapeutics’ exploration of a potential dual primary listing on the Hong Kong Stock Exchange alongside its AIM quote and underpin its strategy to expand in Asia and strengthen its position as a global player in allergy treatments.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics has secured shareholder approval at its general meeting to allot up to 610 million new ordinary shares, representing around 10% of its existing share capital, and to disapply pre-emption rights, giving the board flexibility to conduct a non-pre-emptive equity raise via private placements if it chooses to proceed. While no terms, investors or pricing have yet been agreed and there is no certainty a fundraise will occur, any proceeds would support the company’s strategy to advance treatments for grass and peanut allergies, bolster working capital, and prepare for a planned dual listing in Hong Kong; the company also confirmed it has posted its annual report for the year to 30 June 2025 and made it available on its website.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics has received marketing authorization from the Paul Ehrlich Institut in Germany for its innovative subcutaneous grass pollen allergen immunotherapy, Grassmuno®. This approval marks the first of its kind under Germany’s TAV programme and is expected to significantly impact the German seasonal allergy market, projected to reach approximately US$1 billion by 2030. The approval is a pivotal moment for the company, validating its MATA MPL platform and supporting its expansion strategy into other global markets. Grassmuno® offers a convenient, short-course treatment option for grass pollen allergies, potentially driving business growth in Germany, the company’s largest market.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics has received marketing authorization from the Paul Ehrlich Institut in Germany for its innovative subcutaneous grass pollen allergen immunotherapy, Grassmuno. This approval marks the first of its kind under Germany’s TAV program and is expected to significantly impact the German seasonal allergy market, projected to reach approximately US$1 billion by 2030. The company plans to commercialize Grassmuno in Germany by Q1 2026 and is exploring further regulatory submissions in other global markets. This development is seen as a pivotal moment for Allergy Therapeutics, reinforcing its commitment to clinical excellence and expanding its market presence.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics has announced plans for a potential equity raise by issuing new shares to facilitate its dual listing on the Hong Kong Stock Exchange, expected in the first half of 2026. The company is seeking shareholder approval to issue up to 610 million new shares, which will support its strategy of developing treatments for grass and peanut allergies and address general corporate needs. The outcome of the equity raise remains uncertain, as no agreements with investors have been finalized.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics reported stable financial performance for the year ending June 2025, with revenue remaining flat at £55.0m due to the transition to fully licensed products in Germany. The company strengthened its financial position through strategic investments, securing a new £50m shareholder loan facility, and exploring a dual primary listing in Hong Kong. Progress in R&D was highlighted by advancements in the Grass MATA MPL and VLP Peanut PROTECT trials, positioning the company for future growth and increased market presence.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics announced that its Phase I/IIa PROTECT trial has successfully met its primary safety endpoint at the highest planned treatment dose. Preliminary safety data from 48 participants, including both peanut-allergic and healthy individuals, demonstrated that a 2000-fold increase in dose was safe and well tolerated. The trial’s results support the safety and efficacy of the VLP Peanut treatment, with preparations underway for a Phase IIb trial. This milestone reinforces the company’s confidence in its short-course approach and positions it well for further clinical development.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics is exploring a dual primary listing on the Hong Kong Stock Exchange (HKEX) alongside its current listing on the London Stock Exchange’s AIM market. This move aims to expand the company’s presence in Asia, enhance trading liquidity, and broaden its investor base to include Hong Kong and mainland Chinese investors, aligning with its growth ambitions in the region.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics has commenced patient screening for the second year of its Phase III G308 trial, which evaluates the long-term efficacy and safety of Grass MATA MPL in paediatric patients. This trial is notable for being the first subcutaneous allergen-specific immunotherapy trial designed to assess both short and long-term outcomes in children. The company aims to complete the screening and randomisation by early Q1 2026, with short-term safety data from the first year expected in Q4 2025. The trial is designed to minimize the number of patients receiving a placebo, allowing more children to benefit from active treatment, and is part of a broader $100M investment in grass allergy clinical development.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics has announced the exercise of 1,375,000,000 warrants by lenders, generating £55 million in proceeds used to repay its shareholder debt. The company has also secured a new £50 million uncommitted loan facility, providing financial flexibility through 2030. This transaction strengthens the company’s balance sheet and demonstrates continued support from long-term shareholders, allowing Allergy Therapeutics to focus on key milestones such as regulatory decisions for its allergy immunotherapy products in Germany and progress in its peanut allergy vaccine program.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics has announced positive progress in its Phase I/IIa PROTECT trial for its short-course peanut allergy vaccine candidate, VLP Peanut. The trial has demonstrated a strong safety profile and encouraging early efficacy signals, with no dose-limiting safety or tolerability issues observed. The vaccine candidate has shown potential in reducing allergic responses and inducing a favorable immune response, marking a significant advancement in allergy research. The findings will guide the dose selection for the planned Phase IIb trial, expected to commence in the second half of 2026.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.